• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Nature . Repeated cross-sectional sero-monitoring of SARS-CoV-2 in New York City

tetano

Editor, Senior Moderator
Nature


. 2020 Nov 3.
doi: 10.1038/s41586-020-2912-6. Online ahead of print.
Repeated cross-sectional sero-monitoring of SARS-CoV-2 in New York City


Daniel Stadlbauer[SUP] 1 [/SUP], Jessica Tan[SUP] 1 2 [/SUP], Kaijun Jiang[SUP] 1 [/SUP], Matthew M Hernandez[SUP] 1 [/SUP], Shelcie Fabre[SUP] 3 [/SUP], Fatima Amanat[SUP] 1 2 [/SUP], Catherine Teo[SUP] 1 [/SUP], Guha Asthagiri Arunkumar[SUP] 1 2 [/SUP], Meagan McMahon[SUP] 1 [/SUP], Christina Capuano[SUP] 1 [/SUP], Kathryn Twyman[SUP] 4 [/SUP], Jeffrey Jhang[SUP] 5 [/SUP], Michael D Nowak[SUP] 3 5 [/SUP], Viviana Simon[SUP] 6 7 8 [/SUP], Emilia Mia Sordillo[SUP] 9 10 [/SUP], Harm van Bakel[SUP] 11 12 [/SUP], Florian Krammer[SUP] 13 [/SUP]



Affiliations

Abstract

In late 2019, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) emerged in China and has since caused a pandemic of Coronavirus Disease 2019 (COVID-19). The first COVID-19 case in New York City (NYC) was officially confirmed on March 1[SUP]st[/SUP] 2020 followed by a severe local epidemic.[SUP]1[/SUP] To understand seroprevalence dynamics, we conducted a retrospective, repeated cross-sectional analysis of anti-SARS-CoV-2 spike antibodies in weekly intervals from the beginning of February to July 2020 using more than 10,000 plasma samples from patients at Mount Sinai Hospital in NYC. Here we show the dynamics of seroprevalence in an 'urgent care' (UC) group, enriched for COVID-19 cases during the epidemic, and a 'routine care' group (RC), which more closely represents the general population. Seroprevalence increased at different rates in both groups, with seropositive samples as early as mid-February, and levelled out at slightly above 20% in both groups after the epidemic wave subsided by the end of May. From May to July seroprevalence stayed stable, suggesting lasting antibody levels in the population. Our data suggest an earlier than previously documented introduction of SARS-CoV-2 into NYC and describe the dynamics of seroconversion over the full course of the first pandemic wave in a major metropolitan area.
 
Back
Top Bottom